The bispecific HER2-directed antibody-drug conjugate (ADC) TQB2102 has demonstrated robust antitumor activity and a positive ...

The 2025 American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida, begins on December 6. This year, ...

CLN-049, a novel FLT3/CD3 bispecific T-cell engager, has received fast track designation from the FDA for the treatment of ...

The FDA has granted premarket approval (PMA) to the IsoPSA test, a novel, blood-based in vitro diagnostic kit designed to ...

The FDA has approved pegfilgrastim-unne (Armlupeg) for the treatment of patients with nonmyeloid cancers undergoing treatment ...

Tovorafenib provides durable disease control in pediatric patients with relapsed or refractory low-grade glioma harboring ...

Temferon shows consistent survival metrics in glioblastoma patients with unmethylated MGMT, with 44% reaching 18-month ...

During a live event, Thomas G. Martin, MD, discussed the importance of controlling disease and avoiding barriers to access so patients with multiple myeloma can receive CAR T-cell therapy.

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as demonstrated by the PRESTO, EMBARK, and ENZARAD trials. The PRESTO trial ...

This discussion looks ahead at how the role of PD-1 inhibitors may continue to evolve in the treatment of esophageal squamous ...

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the ...

November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...